Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

How Bristol‑Myers Squibb’s Radioligand & ADC Pipeline Drives Investor Confidence

Explore BMS’s market steadiness and cutting‑edge oncology pipeline—from Opdivo’s checkpoint success to radioligand and ADC breakthroughs that promise future growth.

Dr. Michael Chen

17/07/2026, 03:47

4 minutes to read

LEADER Study Confirms Lecanemab’s Real‑World Efficacy & Safety for Early Alzheimer’s

Real‑world evidence shows LEQEMBI stabilizes early Alzheimer’s disease, with 80 % of patients maintaining disease stage and a favorable safety profile.

Dr. Michael Chen

16/07/2026, 19:05

4 minutes to read

Johnson & Johnson Q2 Earnings: New Oral Immunotherapy & Dual‑Target Drug Propel Growth

Johnson & Johnson Q2 earnings show stable core profits and a boost from new oral anti‑PD‑L1 and dual‑target MAPK drugs, sparking upward analyst outlooks.

Dr. Michael Chen

16/07/2026, 11:53

5 minutes to read

Johnson & Johnson Q2 Earnings Preview: Surge in EPS & $100B 2026 Guidance

J&J Q2 earnings preview: discover how Darzalex and Carvykti drive a 2026 $100 billion sales upgrade, EPS growth, and investor upside amid macro‑economic risk.

Dr. Michael Chen

14/07/2026, 12:32

6 minutes to read

How Eli Lilly’s Cell‑Based Platform Is Reshaping Drug Development

How Eli Lilly’s cell‑based platform strategy drives rapid, scalable therapies across diabetes, oncology and neuro‑degeneration, blending manufacturing innovation with promising early clinical results.

Dr. Michael Chen

13/07/2026, 14:10

4 minutes to read

Alnylam’s Late‑Stage HCM Trial Failure Spurs 6% Share Dip, But Pipeline Persists

Alnylam’s late‑stage HCM trial setback drops shares, yet its diversified RNAi pipeline and strong oncology prospects keep investor optimism alive.

Dr. Michael Chen

12/07/2026, 23:02

3 minutes to read

Vertex Expands Beyond CF: $10B Crinetics Deal & New Triple‑Combination CF Therapy

Vertex expands beyond CF by acquiring Crinetics’ Lanreotide for acromegaly and partnering on a CF triple‑combination therapy—boosting revenue and deepening rare‑disease innovation.

Dr. Michael Chen

12/07/2026, 11:05

4 minutes to read

Gilead Sciences: Antiviral Breakthroughs & Market Outlook 2025–2026

Explore how Gilead Sciences’ focus on antivirals drives stock performance, clinical success, and regulatory wins—insights that shape investor outlook.

Dr. Michael Chen

12/07/2026, 05:01

4 minutes to read

AbbVie Secures EU Approval for Bispecific Antibody Therapy, Boosting Investor Outlook

AbbVie secures EU approval for a high‑response bispecific antibody in relapsed follicular lymphoma, boosting its oncology portfolio and investor appeal.

Dr. Michael Chen

11/07/2026, 23:58

3 minutes to read

Deucravacitinib: BMS Leads the Oral TYK2 Revolution in SLE Therapy

Discover how Bristol‑Myers Squibb’s deucravacitinib, a selective TYK2 inhibitor, offers a steroid‑sparing, oral solution for SLE with proven Phase III renal benefits.

Dr. Michael Chen

11/07/2026, 14:45

4 minutes to read